Zydus Lifesciences Stock in Spotlight Following Semaglutide Production Approval for Export by High Court - Business Insights

Shares of Zydus Lifesciences Limited garnered attention this morning after a High Court ruling authorized the company to produce semaglutide for export to specific nations. The stock saw movement, reflecting investor response to the news.

Zydus Lifesciences Stock in Focus

Zydus Lifesciences Limited's shares were closely watched in morning trading following a High Court order that permits the company to produce semaglutide for export to certain countries. At 11:29 AM, the shares showed a 0.66% increase, trading at Rs 924.30.

Trading activity saw the stock fluctuate within a tight band early on. Shares moved between a daily low of ₹915.45 and a high of ₹926.00 by 11:27 AM, compared to the previous day's closing price of ₹918.20.

Precision tracking for your journey

Join thousands using Shotlee to accurately track GLP-1 medications and side effects.

📱 Get the Shotlee App

Track your GLP-1 medications, peptides, and health metrics on the go with our mobile app!

Download on theApp Store

Get it onGoogle Play

The stock's 52-week range has been between ₹795.00 and ₹1,059.05. The volume of shares traded during the session was 1,03,689.

Source Information

Originally published by Business Upturn.Read the original article →

Keep exploring

More on semaglutide

Articles covering semaglutide dosing, side effects, and clinical updates.

Health & Wellness

Wegovy, Ozempic & Mounjaro: The Real Truth About Weight Loss Meds

A comprehensive guide to GLP-1 receptor agonists, understanding efficacy, managing side effects, and navigating the future of obesity treatment.

7 min read

Health & Wellness

Beyond Ozempic: The Future of Weight Loss & Metabolic Health Innovation

The GLP-1 revolution is just the beginning. This article delves into the cutting-edge advancements poised to reshape the future of weight loss and metabolic health, offering insights for patients and observers alike.

7 min read

Health & Wellness

Beyond Weight Loss: The Next Wave of GLP-1 Drugs

The revolutionary GLP-1 medications have transformed weight management, but the journey of innovation continues. Discover how upcoming drugs aim to enhance patient experience and outcomes.

7 min read

Same topic: Pharmaceuticals

All Pharmaceuticals articles →

Health & Wellness

Pfizer's Berobenatide: A New Monthly GLP-1 for Weight Loss?

Pfizer's investigational GLP-1 receptor agonist, berobenatide, has shown promising results in Phase 2b trials for weight loss. This article delves into the data, its implications for obesity treatment, and what it means for Pfizer's investment outlook.

7 min read

Health & Wellness

Ozempic, Wegovy & Beyond: How GLP-1 Drugs Are Changing What We Eat

The rise of GLP-1 medications is profoundly altering consumer spending habits and food preferences, forcing the grocery industry to adapt. Discover the science behind these changes and how businesses are responding.

7 min read

Health & Wellness

Ozempic & Wegovy's Shadow: The Rise of Gray Market Peptides

The surge in popularity of GLP-1 medications like Ozempic and Wegovy has inadvertently fueled a growing 'gray market' for peptides. This unregulated trade, often facilitated by cryptocurrency, presents significant risks to consumers seeking cheaper alternatives or unapproved compounds.

6 min read